• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

初级保健环境中痛风的管理:您和您的患者需要了解的内容。

Managing gout in the primary care setting: what you and your patients need to know.

机构信息

Collegeville Family Practice, Ursinus College, Collegeville, Penn, USA.

出版信息

Am J Med. 2010 Aug;123(8):S2. doi: 10.1016/j.amjmed.2010.06.005.

DOI:10.1016/j.amjmed.2010.06.005
PMID:20670699
Abstract

The US prevalence of gout, a rapidly progressive inflammatory arthritic condition linked to serum uric acid levels, has grown in recent years, in part due to the increasing prevalence and incidence of predisposing factors in the population, such as metabolic syndrome, obesity, and the use of diuretics. Left untreated, gout can be debilitating and cause deformity. Although a definitive diagnosis requires joint aspiration, only approximately 11% of patients with suspected gout undergo this procedure, and a presumptive diagnosis based on patient medical history and presentation with characteristic symptoms and comorbidities is a reasonable guidelines-based approach that has utility in the primary care setting, where approximately 70% of all cases and nearly 3,000,000 visits occur. The therapeutic standard for patients with recurrent gout flares is urate-lowering therapy (ULT), including allopurinol and the recently introduced febuxostat, the first new treatment for gout in 40 years. Although ULT must be taken consistently to sustain benefits, inadequate dosing and patient nonadherence or intolerance to therapy often lead to treatment failure. It is important that primary care clinicians understand gout diagnosis and therapeutic approaches and can communicate effectively with patients to improve treatment adherence. ONLINE ACCESS: http://cmeaccess.com/cme/ajm_gout_program/ This CME Multimedia Activity is also available through the Website of The American Journal of Medicine (www.amjmed.com). Click on the CME Multimedia Activity button in the navigation bar for full access.

摘要

近年来,美国痛风(一种与血清尿酸水平相关的快速进展性炎症性关节炎疾病)的患病率有所上升,部分原因是代谢综合征、肥胖和利尿剂使用等易患因素在人群中的患病率和发病率不断上升。如果不加以治疗,痛风可能会使人衰弱并导致畸形。虽然关节抽吸术是明确诊断的必要手段,但只有约 11%的疑似痛风患者接受了该程序,根据患者的病史和具有特征性症状和合并症的表现进行推测性诊断是一种合理的基于指南的方法,在初级保健环境中具有实用性,其中约 70%的所有病例和近 300 万次就诊发生在初级保健环境中。对于反复发作的痛风发作患者,治疗标准是降低尿酸治疗(ULT),包括别嘌醇和最近推出的非布司他,这是 40 年来治疗痛风的第一种新疗法。虽然 ULT 必须持续服用才能维持疗效,但剂量不足以及患者不遵医嘱或对治疗不耐受常常导致治疗失败。初级保健临床医生了解痛风的诊断和治疗方法,并能够与患者有效沟通以提高治疗依从性非常重要。在线访问:http://cmeaccess.com/cme/ajm_gout_program/ 本 CME 多媒体活动也可通过《美国医学杂志》(www.amjmed.com)的网站获得。点击导航栏中的 CME 多媒体活动按钮可获得完整访问权限。

相似文献

1
Managing gout in the primary care setting: what you and your patients need to know.初级保健环境中痛风的管理:您和您的患者需要了解的内容。
Am J Med. 2010 Aug;123(8):S2. doi: 10.1016/j.amjmed.2010.06.005.
2
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.病例挑战:痛风、高尿酸血症及其合并症的管理——与专家对话。
Am J Med. 2014 Jan;127(1):S1. doi: 10.1016/j.amjmed.2013.11.001. Epub 2013 Nov 19.
3
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.非布司他或别嘌醇成功长期降低痛风患者尿酸水平的临床疗效与安全性
J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13.
4
The management of gout at an academic healthcare center in Beijing: a physician survey.北京某学术性医疗中心的痛风管理:一项医生调查。
J Rheumatol. 2006 Oct;33(10):2041-9.
5
A survey of the management of gout in primary care.基层医疗中痛风管理的一项调查。
Ir Med J. 2008 May;101(5):147-9.
6
2011 recommendations for the diagnosis and management of gout and hyperuricemia.2011 年痛风和高尿酸血症诊断与治疗的推荐建议。
Phys Sportsmed. 2011 Nov;39(4):98-123. doi: 10.3810/psm.2011.11.1946.
7
Gout--what are the treatment options?痛风——有哪些治疗选择?
Expert Opin Pharmacother. 2009 Jun;10(8):1319-28. doi: 10.1517/14656560902950742.
8
What do I need to know about gout?关于痛风我需要了解些什么?
J Fam Pract. 2010 Jun;59(6 Suppl):S1-8.
9
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.非布司他与别嘌醇及安慰剂对高尿酸血症和痛风患者降低血清尿酸的作用:一项为期28周的III期随机双盲平行组试验。
Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.
10
Refractory gout: what is it and what to do about it?难治性痛风:是什么以及如何应对?
Curr Opin Rheumatol. 2008 Mar;20(2):198-202. doi: 10.1097/BOR.0b013e3282f4eff5.

引用本文的文献

1
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.培戈洛酶治疗常规治疗难治性慢性痛风的长期安全性。
Ann Rheum Dis. 2013 Sep 1;72(9):1469-74. doi: 10.1136/annrheumdis-2012-201795. Epub 2012 Nov 10.